Literature DB >> 15682491

Tumor metastasis and the reciprocal regulation of heparanase gene expression by nuclear factor kappa B in human gastric carcinoma tissue.

Hou-Jun Cao1, Yong Fang, Xing Zhang, Wen-Jun Chen, Wen-Peng Zhou, Hong Wang, Lin-Bo Wang, Jin-Min Wu.   

Abstract

AIM: To investigate whether NF-kappaB is activated in human gastric carcinoma tissues and, if so, to study whether there is any correlation between NF-kappaB activity and heparanase expression in gastric carcinoma.
METHODS: NF-kappaB activation was assayed by immunohistochemical staining in formalin-fixed, paraffin-embedded specimens from 45 gastric carcinoma patients. Electrophoretic mobility shift assay (EMSA) method was used for nuclear protein from these fresh tissue specimens. Heparanase gene expression was quantified using quantitative RT-PCR.
RESULTS: The nuclear translocation of RelA (marker of NF-kappaB activation) was significantly higher in tumor cells compared to adjacent and normal epithelial cells ((41.3+/-3.52)% vs (0.38+/-0.22) %, t = 10.993, P = 0.000<0.05; (41.3+/-3.52)% vs (0+/-0.31)%, t = 11.484, P = 0.000<0.05). NF-kappaB activation was correlated with tumor invasion-related clinicopathological features such as lymphatic invasion, pathological stage, and depth of invasion (Z = 2.148, P = 0.032<0.05; chi(2) = 8.758, P = 0.033<0.05; chi(2) = 18.531, P = 0.006<0.05). NF-kappaB activation was significantly correlated with expression of heparanase gene (r = 0.194, P = 0.046<0.05).
CONCLUSION: NF-kappaB RelA (p65) activation was related with increased heparanase gene expression and correlated with poor clinicopathological characteristics in gastric cancers. This suggests NF-kappaB as a major controller of the metastatic phenotype through its reciprocal regulation of some metastasis-related genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15682491      PMCID: PMC4250607          DOI: 10.3748/wjg.v11.i6.903

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  17 in total

1.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.

Authors:  N Sasaki; T Morisaki; K Hashizume; T Yao; M Tsuneyoshi; H Noshiro; K Nakamura; T Yamanaka; A Uchiyama; M Tanaka; M Katano
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

2.  The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer.

Authors:  L A Ries; P A Wingo; D S Miller; H L Howe; H K Weir; H M Rosenberg; S W Vernon; K Cronin; B K Edwards
Journal:  Cancer       Date:  2000-05-15       Impact factor: 6.860

3.  Major co-localization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils.

Authors:  F Mollinedo; M Nakajima; A Llorens; E Barbosa; S Callejo; C Gajate; A Fabra
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

4.  Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.

Authors:  M D Hulett; C Freeman; B J Hamdorf; R T Baker; M J Harris; C R Parish
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

5.  Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase.

Authors:  D Marchetti; J Li; R Shen
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

6.  Expression of NF-kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions.

Authors:  Wei Wang; He-Sheng Luo; Bao-Ping Yu
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

7.  The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis.

Authors:  Yi Huang; Yong Fang; Jennifer M Dziadyk; James S Norris; Weimin Fan
Journal:  Oncol Res       Date:  2002       Impact factor: 5.574

8.  Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells.

Authors:  Yi Huang; Yong Fang; Jinmin Wu; Jennifer M Dziadyk; Xueming Zhu; Meihua Sui; Weimin Fan
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

9.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

10.  Nuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleus.

Authors:  U Zabel; T Henkel; M S Silva; P A Baeuerle
Journal:  EMBO J       Date:  1993-01       Impact factor: 11.598

View more
  15 in total

1.  Different cellular localization of NF-κB p65 expression as an indicator of different prognoses of stage I-III gastric cancer patients.

Authors:  Fang Zhou; Hongjun Wei; Aiping Ding; Wensheng Qiu; Lingxin Feng; Quan Zhou; Jun Liang; Lu Yue
Journal:  Clin Transl Sci       Date:  2013-05-08       Impact factor: 4.689

2.  Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.

Authors:  Vishnu C Ramani; Israel Vlodavsky; Mary Ng; Yi Zhang; Paola Barbieri; Alessandro Noseda; Ralph D Sanderson
Journal:  Matrix Biol       Date:  2016-03-22       Impact factor: 11.583

3.  Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity.

Authors:  Y Yang; C Gorzelanny; A T Bauer; N Halter; D Komljenovic; T Bäuerle; L Borsig; M Roblek; S W Schneider
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

Review 4.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

Review 5.  Pathogenetic mechanisms in gastric cancer.

Authors:  Jing Shi; Yi-Ping Qu; Peng Hou
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

6.  Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion.

Authors:  Melissa L T Teoh; Matthew P Fitzgerald; Larry W Oberley; Frederick E Domann
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

7.  A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.

Authors:  R C Turkington; C Purcell; C R James; J Millar; E Napier; D Law; R Gallagher; M Morris; R H Wilson; M M Eatock
Journal:  Invest New Drugs       Date:  2013-05-11       Impact factor: 3.850

8.  Oncogenic pathway combinations predict clinical prognosis in gastric cancer.

Authors:  Chia Huey Ooi; Tatiana Ivanova; Jeanie Wu; Minghui Lee; Iain Beehuat Tan; Jiong Tao; Lindsay Ward; Jun Hao Koo; Veena Gopalakrishnan; Yansong Zhu; Lai Ling Cheng; Julian Lee; Sun Young Rha; Hyun Cheol Chung; Kumaresan Ganesan; Jimmy So; Khee Chee Soo; Dennis Lim; Weng Hoong Chan; Wai Keong Wong; David Bowtell; Khay Guan Yeoh; Heike Grabsch; Alex Boussioutas; Patrick Tan
Journal:  PLoS Genet       Date:  2009-10-02       Impact factor: 5.917

9.  High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis.

Authors:  W Weichert; M Boehm; V Gekeler; M Bahra; J Langrehr; P Neuhaus; C Denkert; G Imre; C Weller; H-P Hofmann; S Niesporek; J Jacob; M Dietel; C Scheidereit; G Kristiansen
Journal:  Br J Cancer       Date:  2007-07-10       Impact factor: 7.640

10.  Heparanase is a host enzyme required for herpes simplex virus-1 release from cells.

Authors:  Satvik R Hadigal; Alex M Agelidis; Ghadah A Karasneh; Thessicar E Antoine; Abraam M Yakoub; Vishnu C Ramani; Ali R Djalilian; Ralph D Sanderson; Deepak Shukla
Journal:  Nat Commun       Date:  2015-04-27       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.